Form 4: Supernus Director Sells Shares Post-RSU Vesting

Supernus Pharmaceuticals Director Bethany Sensenig sold 4,475 common stock shares on February 19, 2026, following the vesting of restricted stock units.

Summary

• Supernus Pharmaceuticals, Inc. Director Bethany Sensenig reported transactions on February 19, 2026.
• Sensenig acquired 4,475 shares of common stock at a price of $0, which resulted from the vesting of restricted stock units (RSUs).
• Immediately following the vesting, Sensenig disposed of 1,217 shares of common stock at a weighted average price of $50.31 per share.
• The shares sold at $50.31 ranged from $49.83 to $50.71 across multiple transactions.
• Sensenig subsequently disposed of an additional 3,258 shares of common stock at a weighted average price of $51.27 per share.
• The shares sold at $51.27 ranged from $50.98 to $51.56 across multiple transactions.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on May 15, 2025.
• Following these transactions, Sensenig's direct beneficial ownership of Supernus common stock is 0 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It represents a routine insider transaction related to equity compensation and a pre-planned sale, rather than a discretionary trade based on new material information.

Positives

• The vesting of 4,475 restricted stock units represents a successful compensation event for Director Bethany Sensenig.
• The sale of shares at market prices demonstrates liquidity for the director's equity compensation.

Negatives

• Director Bethany Sensenig no longer holds any directly beneficially owned shares of Supernus common stock following these transactions, which could be interpreted as a lack of direct equity alignment, although this is often part of pre-planned compensation strategies.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under a Rule 10b5-1 plan, are common occurrences in publicly traded companies, especially within the pharmaceutical sector where executive compensation often includes equity components like restricted stock units. These pre-arranged plans are designed to allow insiders to sell shares without concerns about insider trading allegations.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan aligns with standard corporate governance practices for managing insider stock sales in a compliant and transparent manner, similar to plans adopted by executives at peer pharmaceutical companies like Pfizer or Merck.

Stakeholder Impact

• Shareholders: The sale by a director, while pre-planned, slightly increases the float of shares but is unlikely to have a significant impact on the overall share price given the volume relative to the company's market capitalization.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Supernus Pharmaceuticals, SUPN, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Stock Sale, Director Transaction, 10b5-1 Plan